Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA7 | P43166 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MITF | O75030 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KCNA1 | Q09470 | 4/20 | 0.40 |
| ▸ | KCNAB1 | Q14722 | 4/20 | 0.40 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL490066 | 0.92 | ESR1 (0.65) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL30471045 | 0.92 | ESR2 (0.65) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL30408119 | 0.92 | ESR1 (0.65) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL6436222 | 0.92 | ESR2 (0.65) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL3893392 | 0.87 | ESR1 (0.55) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL7838175 | 0.84 | ESR1 (0.55) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL15399197 | 0.83 | ESR1 (0.49) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL4040738 | 0.81 | NOTUM (0.47) | CA1CA2CA7CA9NPC1 | |
| SCHEMBL4231312 | 0.81 | ESR2 (0.68) | ESR1ESR2PKMCA1CA2 | |
| SCHEMBL2993408 | 0.81 | ESR1 (0.68) | ESR1ESR2PKMCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504392-B2 | 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use | GLAXO GROUP LIMITED (GB) | 2009-03-17 | — | — | US | disclosed |
| EP-1727801-B1 | PIPERAZINES USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2009-02-18 | — | — | EP | disclosed |
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | GLAXO GROUP LIMITED | 2008-10-30 | — | — | US | disclosed |
| EP-1511727-B1 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. | 2007-02-08 | — | — | US | disclosed |
| US-20050261279-A1 | Compounds | GLAXO GROUP LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| US-20050245507-A1 | 7-Phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | GLAXO GROUP LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1511727-A2 | AROMATIC SULFONES AND THEIR MEDICAL USE | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1509504-A1 | 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| EP-0822934-B1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | PFIZER RES & DEV (IE) | 2000-02-09 | — | — | EP | disclosed |
| US-5861393-A | THROMBIN INHIBITORS; VASCULAR, CARDIOVASCULAR, NERVOUS SYSTEM AND BRAIN DISORDERS; ANTIISCHEMIC AND ANTIINFLAMMATORY AGENTS; RESTENOSIS | PFIZER INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5798352-A | Antithrombotic amidinotetrahydropyridylalanine derivatives | PFIZER INC. (US) | 1998-08-25 | — | — | US | disclosed |
| US-5750520-A | SELECTIVE THROMBIN INHIBITORS; WOUND HEALING AGENTS | PFIZER INC. (US) | 1998-05-12 | — | — | US | disclosed |
| EP-0822934-A1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-02-11 | — | — | EP | disclosed |
| EP-0728132-B1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1997-07-16 | — | — | EP | disclosed |
| WO-1996033993-A1 | ANTITHROMBOTIC AMIDINOTETRAHYDROPYRIDYLALANINE DERIVATIVES | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1996-10-31 | — | — | WO | disclosed |
| EP-0728132-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LTD (GB) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013274-A1 | ANTITHROMBOTIC AMIDINOPHENYLALANINE AND AMIDINOPYRIDYLALANINE DERIVATIVES | PFIZER LIMITED (GB) | 1995-05-18 | — | — | WO | disclosed |
| US-4085225-A | Oxime ethers having anti-depressive activity | U.S. PHILIPS CORPORATION (US) | 1978-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269197-A1 | antipsychotic agents; phenylsulfonyl compounds; 7-Methoxy-8-(3-phenoxy-benzenesulfonyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; schizophrenia | SIGMAR1, CBR3, CBR1 | ESR1 312/4885ESR2 324/4885PKM 3039/4885 |
| US-20050261279-A1 | Compounds | CBR1, CBR3, OXER1 | ESR1 45/4885ESR2 54/4885PKM 3035/4885 |
| US-20050176759-A1 | 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment cns disorders | MPL, HTR2B, PDGFRB | ESR1 2089/4885ESR2 1480/4885PKM 3595/4885 |
| US-20070032500-A1 | Therapeutic agents useful for treating pain | TRPV1, OPRL1, CNR2 | ESR1 1646/4885ESR2 594/4885PKM 2979/4885 |
| US-20050245507-A1 | 7-Phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents | HTR3C, SIGMAR1, CHRM1 | ESR1 546/4885ESR2 1024/4885PKM 1360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.